PREVALENCE OF THYROID DYSFUNCTION IN CHRONIC KIDNEY DISEASE

G. Prabhu1, Nandhini Priyanka B2, Rajaprabhu J, Linto Mathew Thomas4

1Reader, Department of Medicine, Rajah Muthiah Medical College.
2Postgraduate, Department of Medicine, Rajah Muthiah Medical College.
3Pharm. D (Internship), Annamalai University.
4Pharm. D (Internship), Annamalai University.

ABSTRACT

AIM

The present study was aimed to study the Prevalence of thyroid dysfunction in chronic kidney disease at RMMCH.

METHODS AND MATERIALS

The data was collected from the patients reported to dialysis unit, OPD and wards in Rajah Muthiah Medical College Hospital, Annamalai University. During a period of 2 months, 60 patients who had undergone treatment for chronic kidney disease were followed up (Male-24, Female-36). Patients with chronic kidney disease confirmed by Ultrasonography of kidney and Creatinine clearance, patients on haemodialysis/renal replacement therapy or Conservative treatment were included in this study. Patients on Thyroid replacement/Anti-Thyroid drugs, Age < 30 years, Patients on steroid/hormone therapy and Malignancy were excluded in this study.

RESULTS

60 patients (24 males and 36 females) were included in the study. From the study, incidence rate was identified more in the age group of 51-60 years of age. As per the study conducted, about 12 patients were non-diabetic and 9 were not hypertensives; 36 patients undergone the treatment of haemodialysis and 24 patients were on conservative treatment. In our study, there were 13 patients (21.66%) with hypothyroidism. Of which, clinical features and investigations revealed 6 patients with clinical hypothyroidism and 7 patients with subclinical hypothyroidism with stages 1-5 CKD. No patient had clinical evidence of hyperthyroidism.

CONCLUSION

In summary, the present study finds hypothyroidism to be very common in CKD patients and reveals the significant association between CKD progression and thyroid dysfunction.

KEYWORDS

Thyroid Dysfunction, Chronic Kidney Disease, Hypothyroidism.


INTRODUCTION

Abnormalities in thyroid function tests are frequently encountered in uraemia. However, the overlap in symptomatology between the uremic syndrome and hypothyroidism requires a cautious interpretation of these tests. Nevertheless, it is ordinarily possible in the individual uremic patient to assess thyroid status accurately by physical diagnosis and thyroid function testing. Epidemiologic data suggests that predialysis patients with chronic kidney disease have an increased rate of hypothyroidism.[1-4] Patients with chronic renal failure often have signs and symptoms suggestive of thyroid dysfunction.

...These findings include dry skin, sallow complexion, low temperature, cold intolerance, decreased basal metabolic rate, lethargy, fatigue, oedema and hyporeflexia. Various studies of thyroid functions in uremic patients have been carried out, which have shown conflicting results. Hyperthyroidism, hypothyroidism and euthyroid state have all been reported.[5-7] Chronic kidney disease is associated with multiple disturbances in thyroid metabolism that are manifested in low serum free and total T3 levels and normal in total T3 and free T4 concentrations. The serum TSH concentration is normal and most patients are euthyroid.[8] Free fatty acids and heparin also interfere with T4 binding to TBG. Thus, the routine use of heparin to prevent clotting in the dialysis tubing may explain the transient elevation in serum T4 levels that commonly occurs during haemodialysis.[9]

Thyroid Hormone Metabolism and the Kidney

Due to reduced deiodinase activity, tissue and circulating levels of the active form of the thyroid hormone (T3) is low in kidney failure.[10] Because of reduced renal excretion, inorganic iodide generated by residual deiodinase activity accumulates in stage 4 and 5 CKD, which in turn dampens thyroid hormone synthesis. On the other hand, accumulation of toxic uraemic solutes alters the central (Hypothalamic)
control of the pituitary gland, and the TSH response to 
thyrotropin releasing hormone is normal in patients with 
kidney failure.[11] In contrast, the thyroid–pituitary feedback 
loop seems to remain intact, because steady-state plasma 
TSH remains substantially normal and TSH undergoes the 
expected rise after thyroidectomy in these patients.[7] Central 
effects apart, toxic uraemic solutes such as urea, creatinine, 
indoles and phenols inhibit protein binding of T4.[12] 
Furthermore, studies in the last decade showed that systemic 
inflammation[13,14] and metabolic acidosis[15] may alter 
thyroid function in CKD patients.

METHODS AND MATERIALS
A total number of 60 randomly selected patients with chronic 
kidney disease attending dialysis unit, OPD and admitted in 
Rajah Muthiah Medical College Hospital were studied 
between April 2016 to June 2016. Study population 
consisting of 24 male and 36 female patients who were 
diagnosed cases of chronic kidney disease. Age range was 31- 
70 years. Most patients in this study were on conservative 
treatment and a few were on renal replacement therapy 
(Peritoneal or haemodialysis).

Inclusion Criteria
1. Patients with chronic kidney disease confirmed by 
   Ultrasonography of kidney and Creatinine clearance.
2. Patients on haemodialysis, Renal replacement therapy, 
   Conservative (Medical treatment).

Exclusion Criteria
1. Patients on thyroid replacement/anti-thyroid drugs.
2. Age <30 years.
3. Patients on steroid/hormone therapy.
4. Malignancy.

Data Collection
Data was collected from the patients reported to dialysis unit, 
OPD and wards in RMMC, Annamalai University. Initially, 
we recorded demographic information (Name, sex, age, etc.), 
the presence of kidney disease and its complications, past 
history (Such as acute and chronic infections or chronic 
diseases) of all enrolled subjects. Blood samples were 
collected from the peripheral vein and analysed for indicators 
of renal function (Creatinine, Cr; Blood Urea Nitrogen, BUN; 
Uric Acid, UA), and for thyroid function (Serum free T3 (FT3), 
free T4 (FT4), and Thyroid Stimulating Hormone (TSH). 
Routine urine samples were taken and urinary protein 
assayed; kidney ultrasound was also performed to assist in 
evaluating the severity of illness. Thyroid function tests were 
performed using an electrochemiluminescence assay. The 
normal reference ranges for FT3, FT4 and TSH in our 
hospital’s clinical laboratory were 1.4-4.4 pg/mL, 0.7-2.0 
ng/dL, and 0.30-5.5 µIU/mL respectively. The data was 
statistically analysed.

RESULTS

<table>
<thead>
<tr>
<th>Age</th>
<th>No. of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>31-40 years</td>
<td>10</td>
</tr>
<tr>
<td>41-50 years</td>
<td>18</td>
</tr>
<tr>
<td>51-60 years</td>
<td>21</td>
</tr>
<tr>
<td>61-70 years</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
</tr>
</tbody>
</table>

Table 1: Age & Sex Wise Distribution

<table>
<thead>
<tr>
<th>Age</th>
<th>Duration of Diabetes Mellitus</th>
<th>No. of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2 years</td>
<td>1.4-4.4</td>
<td>1.83±0.018</td>
</tr>
<tr>
<td>2-5 years</td>
<td>0.7-2.0</td>
<td>1.5±0.51</td>
</tr>
<tr>
<td>5-10 years</td>
<td>0.30-5.5</td>
<td>3.62±2.48</td>
</tr>
</tbody>
</table>

Table 2: Age vs. Duration of DM

<table>
<thead>
<tr>
<th>Variables</th>
<th>No. of Patients</th>
<th>Reference Range</th>
<th>±s</th>
</tr>
</thead>
<tbody>
<tr>
<td>FT3 (pg/mL)</td>
<td>60</td>
<td>1.4-4.4</td>
<td>1.83±0.018</td>
</tr>
<tr>
<td>FT4 (ng/dL)</td>
<td>60</td>
<td>0.7-2.0</td>
<td>1.5±0.51</td>
</tr>
<tr>
<td>TSH (µIU/mL)</td>
<td>60</td>
<td>0.30-5.5</td>
<td>3.62±2.48</td>
</tr>
</tbody>
</table>

Table 4: Thyroid Function in (n=60) Enrolled Subjects

<table>
<thead>
<tr>
<th>CKD Stage</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1</td>
<td>10</td>
<td>16.6%</td>
</tr>
<tr>
<td>Stage 2</td>
<td>7</td>
<td>11.6%</td>
</tr>
<tr>
<td>Stage 3</td>
<td>2</td>
<td>3.3%</td>
</tr>
<tr>
<td>Stage 4</td>
<td>5</td>
<td>8.3%</td>
</tr>
<tr>
<td>Stage 5</td>
<td>36</td>
<td>60%</td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 5: CKD Stage vs. No. of Patients

<table>
<thead>
<tr>
<th>Treatment</th>
<th>No. of Patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemodialysis (Stage 5)</td>
<td>36</td>
<td>60%</td>
</tr>
<tr>
<td>Conservative treatment (Stage 1-4)</td>
<td>24</td>
<td>40%</td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 6: Treatment of CKD
DISCUSSION
A total number of 60 patients were enrolled in this study. The mean age was 50.65±9.40 years. There were 36 female patients and 24 male patients as compared to other study, which enrolled 14,623 patients, the mean age was 48.7±18.9 years. There were 7671 women and 6952 men (Lo et al).[10] The maximum number of patients were in the age group of 51-60 years (21 patients), while the female patients were more in this group than in male. Minimum number of patients were in the age group of 31-40 years (10 patients). As per the study conducted, about 12 patients were non-diabetic and 9 were not hypertensive. But diabetes mellitus and hypertensive nephropathy were contributing too significantly for the cause of CKD. In our study, prevalence of diabetes mellitus and hypertension was 80 and 85% in stage 1-5 CKD patients. In a similar study conducted by (Khatiwada et al.), prevalence of diabetes mellitus and hypertension was 45.8 and 63.8% in stage 3; 40.3 and 72.4% in stage 4; 60 and 80% in stage 5 CKD patients respectively.[16] In our study, mean variables in thyroid function tests were FT3 (1.83±0.018), FT4 (1.5±0.51) and TSH (3.62±2.48). In the study conducted, 36 patients underwent the treatment of haemodialysis and 24 patients were on conservative treatment. In our study, there were 13 patients (21.66%) with hypothyroidism of which clinical features and investigation revealed 6 patients with clinical hypothyroidism and 7 patients with subclinical hypothyroidism of stages 1-5 CKD. A similar study showed 8 patients (16%) with hypothyroidism were from stages 4 and 5 CKD (Ali A. Allawi).[17] In our study we noted a significant decrease in mean FT3, FT4 and increase in TSH mean. Also in our study we noted 13 patients, in which 5 patients were managed by conservative treatment and 8 with haemodialysis. No patient demonstrated hyperthyroidism factors and investigations also did not reveal clear evidence of hyperthyroidism in this study.

CONCLUSION
The present study was aimed to study the prevalence of thyroid dysfunction in chronic kidney disease at RMMCH. In summary, the present study finds hypothyroidism to be very common in CKD patients and reveals the significant association between CKD progression and thyroid dysfunction.

REFERENCES